| First Author | Nomura E | Year | 2019 |
| Journal | Neuroscience | Volume | 415 |
| Pages | 31-43 | PubMed ID | 31344397 |
| Mgi Jnum | J:283014 | Mgi Id | MGI:6384546 |
| Doi | 10.1016/j.neuroscience.2019.06.025 | Citation | Nomura E, et al. (2019) Imaging Hypoxic Stress and the Treatment of Amyotrophic Lateral Sclerosis with Dimethyloxalylglycine in a Mice Model. Neuroscience 415:31-43 |
| abstractText | Hypoxia inducible factor-1alpha (HIF-1alpha) is a key transcription factor that maintains oxygen homeostasis. Hypoxic stress is related to the pathogenesis of amyotrophic lateral sclerosis (ALS), and impaired HIF-1alpha induces motor neuron degeneration in ALS. Dimethyloxalylglycine (DMOG) upregulates the stability of HIF-1alpha expression and shows neuroprotective effects, but has not been used in ALS as an anti-hypoxic stress treatment. In the present study, we investigated hypoxic stress in ALS model mice bearing G93A-human Cu/Zn superoxide dismutase by in vivo HIF-1alpha imaging, and treated the ALS mice with DMOG. In vivo HIF-1alpha imaging analysis showed enhanced hypoxic stress in both the spinal cord and muscles of lower limbs of ALS mice, even at the pre-symptomatic stage. HIF-1alpha expression decreased as the disease progressed until 126days of age. DMOG treatment significantly ameliorated the decrease in HIF-1alpha expression, the degeneration of both spinal motor neurons and myofibers in lower limbs, gliosis and apoptosis in the spinal cord. This was accompanied by prolonged survival. The present study suggests that in vivo bioluminescence resonance energy transfer (BRET) HIF-1alpha imaging is useful for evaluating hypoxic stress in ALS, and that the enhancement of HIF-1alpha is a therapeutic target for ALS patients. |
